ImmuCell (ICCC) vs Q/C Technologies (QCLS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
ImmuCell is the larger company by market cap ($88.6 million vs $5.2 million), about 17.0 times the size. On valuation, Q/C Technologies trades at a lower trailing P/E (0.2x vs 139.3x for ImmuCell).
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | ICCC | QCLS |
|---|---|---|
| Share price | $9.75 | $0.6367 |
| Market cap | $88.55M | $5.21M |
| 1-day change | +0.62% | +0.74% |
| YTD return | +57.56% | — |
| 1-year return | +50.23% | — |
| 5-year return | +4.42% | — |
| P/E ratio (TTM) | 139.29 | 0.24 |
| EPS (TTM) | $0.07 | $2.62 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.10 | $8.17 |
| 52-week low | $4.52 | $0.42 |
| Distance from 52-week high | -19.42% | -92.21% |
| Average volume | 22.88K | 4.97M |
| Shares outstanding | 9.08M | 8.19M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ImmuCell is about 17.0 times larger than Q/C Technologies by market value ($88.55M vs $5.21M).
- ImmuCell trades at a higher earnings multiple (139.3x vs 0.2x trailing P/E).
ICCC vs QCLS FAQ
Which is bigger, ImmuCell or Q/C Technologies?
ImmuCell (ICCC) is larger, with a market capitalization of $88.55M compared with $5.21M for Q/C Technologies (QCLS).
Which has the lower P/E ratio, ICCC or QCLS?
QCLS has the lower trailing P/E at 0.2, versus 139.3 for ICCC. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are ImmuCell and Q/C Technologies in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.